Articles producció científica> Medicina i Cirurgia

Prevalence and factors associated with SARS-CoV-2 seropositivity in the Spanish HIV Research Network Cohort

  • Datos identificativos

    Identificador: imarina:9241735
    Handle: https://hdl.handle.net/20.500.11797/imarina9241735
    Autores:
    Berenguer, JDiez, CMartin-Vicente, MMican, RPerez-Elias, MJGarcia-Fraile, LJVidal, FSuarez-Garcia, IPodzamczer, DDel Romero, JPulido, FIribarren, JAGutierrez, FPoveda, EGalera, CIzquierdo, RAsensi, VPortilla, JLopez, JCArribas, JRMoreno, SGonzalez-Garcia, JResino, SJarrin, I
    Resumen:
    Objectives: We aimed to assess the prevalence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and factors associated with seropositivity and asymptomatic coronavirus disease 2019 (COVID-19) among people with HIV (PWH).Methods: This was a cross-sectional study carried out within the cohort of the Spanish HIV Research Network. Participants were consecutive PWH with plasma collected from 1st April to 30th September 2020. We determined SARS-CoV-2 antibodies (Abs) in plasma. Illness severity (NIH criteria) was assessed by a review of medical records and, if needed, participant interviews. Multivariable logistic regression analysis was used to identify predictors of seropositivity among the following variables: sex, age, country of birth, education level, comorbidities (hypertension, chronic heart disease, diabetes mellitus, non-AIDS-related cancer, chronic kidney disease, cirrhosis), route of HIV acquisition, prior AIDS, CD4+ cell count, HIV viral load, nucleoside/nucleotide reverse transcriptase inhibitor (N [t]RTI) backbone, type of third antiretroviral drug, and month of sample collection.Results: Of 1076 PWH (88.0% males, median age 43 years, 97.7% on antiretroviral therapy, median CD4+ 688 cells/mm(3), 91.4% undetectable HIV viral load), SARS-CoV-2 Abs were detected in 91 PWH, a seroprevalence of 8.5% (95%CI 6.9-10.3%). Forty-five infections (45.0%) were asymptomatic. Variables independently associated with SARS-CoV-2 seropositivity were birth in Latin American countries versus Spain (adjusted odds ratio (aOR) 2.30, 95%CI 1.41-3.76, p 0.001), and therapy with tenofovir disoproxil fumarate plus emtricitabine (TDF/FTC) versus tenofovir alafenamide (TAF)/FTC as the N(t)RTI backbone (aOR 0.49, 95%CI 0.26-0.94, p 0.031).Conclusions: Many SARS-CoV-2 infections

  • Otros:

    Autor según el artículo: Berenguer, J; Diez, C; Martin-Vicente, M; Mican, R; Perez-Elias, MJ; Garcia-Fraile, LJ; Vidal, F; Suarez-Garcia, I; Podzamczer, D; Del Romero, J; Pulido, F; Iribarren, JA; Gutierrez, F; Poveda, E; Galera, C; Izquierdo, R; Asensi, V; Portilla, J; Lopez, JC; Arribas, JR; Moreno, S; Gonzalez-Garcia, J; Resino, S; Jarrin, I
    Departamento: Medicina i Cirurgia
    Autor/es de la URV: Vidal Marsal, Francisco
    Palabras clave: Seroprevalence Serology Sars-cov-2 Risk-factors Infection Hiv Covid-19 Coronavirus disease 2019 Clinical characteristics Antibodies
    Resumen: Objectives: We aimed to assess the prevalence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and factors associated with seropositivity and asymptomatic coronavirus disease 2019 (COVID-19) among people with HIV (PWH).Methods: This was a cross-sectional study carried out within the cohort of the Spanish HIV Research Network. Participants were consecutive PWH with plasma collected from 1st April to 30th September 2020. We determined SARS-CoV-2 antibodies (Abs) in plasma. Illness severity (NIH criteria) was assessed by a review of medical records and, if needed, participant interviews. Multivariable logistic regression analysis was used to identify predictors of seropositivity among the following variables: sex, age, country of birth, education level, comorbidities (hypertension, chronic heart disease, diabetes mellitus, non-AIDS-related cancer, chronic kidney disease, cirrhosis), route of HIV acquisition, prior AIDS, CD4+ cell count, HIV viral load, nucleoside/nucleotide reverse transcriptase inhibitor (N [t]RTI) backbone, type of third antiretroviral drug, and month of sample collection.Results: Of 1076 PWH (88.0% males, median age 43 years, 97.7% on antiretroviral therapy, median CD4+ 688 cells/mm(3), 91.4% undetectable HIV viral load), SARS-CoV-2 Abs were detected in 91 PWH, a seroprevalence of 8.5% (95%CI 6.9-10.3%). Forty-five infections (45.0%) were asymptomatic. Variables independently associated with SARS-CoV-2 seropositivity were birth in Latin American countries versus Spain (adjusted odds ratio (aOR) 2.30, 95%CI 1.41-3.76, p 0.001), and therapy with tenofovir disoproxil fumarate plus emtricitabine (TDF/FTC) versus tenofovir alafenamide (TAF)/FTC as the N(t)RTI backbone (aOR 0.49, 95%CI 0.26-0.94, p 0.031).Conclusions: Many SARS-CoV-2 infections among PWH were asymptomatic, and birth in Latin American countries increased the risk of SARS-CoV-2 seropositivity. Our analysis, adjusted by comorbidities and other variables, suggests that TDF/FTC may prevent SARS-CoV-2 infection among PWH. (C) 2021 The Author(s). Published by Elsevier Ltd on behalf of European Society of Clinical Microbiology and Infectious Diseases.
    Áreas temáticas: Saúde coletiva Química Odontología Microbiology (medical) Microbiology Medicine (miscellaneous) Medicina veterinaria Medicina iii Medicina ii Medicina i Interdisciplinar Infectious diseases Farmacia Ciências biológicas iii Ciências biológicas ii Ciências biológicas i Ciências ambientais Ciências agrárias i Biotecnología Astronomia / física
    Acceso a la licencia de uso: https://creativecommons.org/licenses/by/3.0/es/
    Direcció de correo del autor: francesc.vidal@urv.cat
    Identificador del autor: 0000-0002-6692-6186
    Fecha de alta del registro: 2024-07-27
    Versión del articulo depositado: info:eu-repo/semantics/publishedVersion
    Enlace a la fuente original: https://www.clinicalmicrobiologyandinfection.com/article/S1198-743X(21)00343-8/fulltext#%20
    URL Documento de licencia: https://repositori.urv.cat/ca/proteccio-de-dades/
    Referencia al articulo segun fuente origial: Clinical Microbiology And Infection. 27 (11): 1678-1684
    Referencia de l'ítem segons les normes APA: Berenguer, J; Diez, C; Martin-Vicente, M; Mican, R; Perez-Elias, MJ; Garcia-Fraile, LJ; Vidal, F; Suarez-Garcia, I; Podzamczer, D; Del Romero, J; Puli (2021). Prevalence and factors associated with SARS-CoV-2 seropositivity in the Spanish HIV Research Network Cohort. Clinical Microbiology And Infection, 27(11), 1678-1684. DOI: 10.1016/j.cmi.2021.06.023
    DOI del artículo: 10.1016/j.cmi.2021.06.023
    Entidad: Universitat Rovira i Virgili
    Año de publicación de la revista: 2021
    Tipo de publicación: Journal Publications

  • Palabras clave:

    Infectious Diseases,Medicine (Miscellaneous),Microbiology,Microbiology (Medical)
    Seroprevalence
    Serology
    Sars-cov-2
    Risk-factors
    Infection
    Hiv
    Covid-19
    Coronavirus disease 2019
    Clinical characteristics
    Antibodies
    Saúde coletiva
    Química
    Odontología
    Microbiology (medical)
    Microbiology
    Medicine (miscellaneous)
    Medicina veterinaria
    Medicina iii
    Medicina ii
    Medicina i
    Interdisciplinar
    Infectious diseases
    Farmacia
    Ciências biológicas iii
    Ciências biológicas ii
    Ciências biológicas i
    Ciências ambientais
    Ciências agrárias i
    Biotecnología
    Astronomia / física

  • Documentos:

    DocumentPrincipal

  • Cerca a google

    Search to google scholar